Journal article
A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis
Abstract
BACKGROUND: Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib - a selective Janus kinase (JAK) inhibitor that blocks the signaling of several cytokines, including interleukin-6 and interferon-γ - are unknown in patients with giant-cell arteritis.
METHODS: We randomly assigned patients with new-onset or relapsing giant-cell arteritis, in a 2:1:1 ratio, to receive upadacitinib at …
Authors
Blockmans D; Penn SK; Setty AR; Schmidt WA; Rubbert-Roth A; Hauge EM; Keen HI; Ishii T; Khalidi N; Dejaco C
Journal
The New England Journal of Medicine, Vol. 392, No. 20, pp. 2013–2024
Publisher
Massachusetts Medical Society
Publication Date
May 29, 2025
DOI
10.1056/nejmoa2413449
ISSN
0028-4793